Navigation Links
Potential blood test for chronic sinusitis identified
Date:4/14/2008

A protein profile has been identified in the blood of chronic sinusitis sufferers that may enable physicians to objectively diagnosis and treat the disease, researchers say.

They used a sophisticated research tool that rapidly assesses expression of large numbers of proteins and found among 96 chronic sinusitis patients a profile missing in 38 healthy controls.

We can diagnose this disease with a totally objective test that does not depend on symptoms or observations, says Dr. Stilianos E. Kountakis, vice chair of the Department of Otolaryngology-Head and Neck Surgery in the Medical College of Georgia School of Medicine. He is corresponding author on the study published in the March/April issue of American Journal of Rhinology.

Diagnosing this chronically irritating disease, characterized by dripping noses, sinus pressure, congestion and difficulty breathing, currently is rather subjective. Patients talk about symptoms and doctors look at their sinuses with an endoscope and probably a computerized tomography scan. (O)verall management of (chronic sinusitis) is still hampered by the lack of quantifiable, molecular and genetic markers to aid in screening, researchers write.

To be classified chronic, the misery has to continue for at least 12 weeks. Causes include bacterial infections, respiratory inflammation, sinus polyps and mucosal disease. Some causes, such as polyps and asthma, have a genetic predisposition. You may have a bacterial infections, allergies, mechanical problems, Dr. Kountakis says. There are numerous genes that control respiratory function. Any of these things can go wrong to predispose the patient to develop chronic sinusitis.

Treating it isnt much more straightforward. Surgery can help correct anatomical causes such as deviated septums or polyps. However, there are no FDA-aproved drugs specifically to treat chronic sinusitis. Instead, physicians use drugs that treat symptoms: steroid sprays for inflammation, mucus thinners, saline irrigation, etc. Its difficult to show drugs are effective because its difficult to group patients together and measure their disease, says Dr. Kountakis.

He hopes further studies will enable both, revealing signature protein profiles for different types of chronic sinusitis as well as the degree of disease. The bottom line is we want to group patients according to their disease rather than just the general term chronic sinusitis, Dr. Kountakis says. If we can find a way to classify patients, group them together based on the specific disease they have, maybe we can get better outcomes and treat patients with better efficiency.

These objective measures should allow monitoring the effectiveness of current therapies and objectively reviewing new ones, he says.

In fact, even getting a handle on disease incidence is tough. The National Health Interview Survey, based on self-reports, says 14 to 16 percent of people in the United States have chronic sinusitis. A population-based study of the Olmsted County, Minnesota published in 2004 in Archives of Otolaryngology-Head & Neck Surgery put the incidence at 2 percent.

For this study, researchers analyzed protein expression in the blood using surface enhanced laser desorption ionization time-of-flight mass spectroscopy or SELDI-TOF-MS. The test is about 88 percent accurate.


'/>"/>

Contact: Toni Baker
tbaker@mcg.edu
706-721-4412
Medical College of Georgia
Source:Eurekalert  

Related medicine news :

1. Medical errors cost US $8.8B, result in 238,337 potentially preventable deaths: HealthGrades study
2. Stem cell research leads to potential new therapy for rare blood disorder
3. New research shows benefits of ultrasound contrast agents outweigh potential risk to heart patients
4. Angina drug potentially useful against heart rhythm disorders
5. Neuronal regulators offer potential targets for cancer
6. Companies Not Fully Tapping Potential of Onsite Health Centers
7. Study Finds Potential Cause of Age-Related Macular Degeneration
8. More Clinical Data Required to Support European Approval of Desvenlafaxine as a Potential Treatment for Vasomotor Symptoms
9. New potential treatment for muscular dystrophy appears to be safe
10. Regenstrief Institute tapped by CDC to combat potentially catastrophic disease outbreaks
11. Research shows promise for potential new gene therapy strategy for muscle-wasting diseases
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Potential blood test for chronic sinusitis identified
(Date:2/8/2016)... , ... February 08, 2016 , ... Delta Dental of ... help combat pancreatic cancer. , Gary D. Radine, who recently retired as president and ... American Cancer Society’s 2015 CEO of the Year , helped lead the effort ...
(Date:2/8/2016)... ... ... Remember the old saying “rub some dirt on it”? Perhaps you should try ... Clay” the health benefits of integrating clay into a daily diet are numerous, as ... motivational speaker, Perry A~ has since dedicated her life to learning about the benefits ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... wide variety of organizations. DocuSyst provides a cloud hosted environment for FileHold ... installations include integration with various 3rd party applications using the FileHold web services ...
(Date:2/8/2016)... ... February 08, 2016 , ... GrassrootsHealth published data from ... type 2 diabetes in the GrassrootsHealth cohort with substantially higher vitamin D levels ... in public health,” states Carole Baggerly, Director of GrassrootsHealth, “the safety and ...
(Date:2/8/2016)... ... ... TopConsumerReviews.com recently awarded their highest five-star rating to a product from Healing ... cluster of melanin when exposed to sunlight. Although most moles are benign and harmless, ... Historically, mole removal has involved a painful, often expensive visit to the ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Feb. 8, 2016   GS1 US will ... guide them through GS1 Standards implementation to address the ... Unique Device Identification (UDI) rule. Scott ... Beth Gibson , senior director industry development, medical devices, ... director, GS1 US --> Scott ...
(Date:2/8/2016)... Feb. 8, 2016 Nueterra, the ... specialized in the development of equity partnerships ... it has divided its interests between two ... Capital will continue the founding company,s private ... operate a national system of integrated provider ...
(Date:2/8/2016)... Pa. , Feb. 8, 2016   ... November Research Group (NRG),s pharmacovigilance technology services ... system-related consulting services and an Oracle Argus Specialized ... services to Life Sciences companies. ... and expands HighPoint,s life sciences capabilities and provides ...
Breaking Medicine Technology: